CARsgen Therapeutics Holdings Future Growth

Future criteria checks 2/6

CARsgen Therapeutics Holdings is forecast to grow earnings and revenue by 23.4% and 114.9% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be -97% in 3 years.

Key information

23.4%

Earnings growth rate

24.0%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	114.9%
Future return on equity	-97.0%
Analyst coverage	Low
Last updated	30 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:CRTH.F - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,162	-328	N/A	N/A	2
12/31/2025	720	-622	N/A	N/A	2
12/31/2024	75	-577	N/A	N/A	1
6/30/2024	6	-695	-579	-569	N/A
3/31/2024	3	-721	-522	-512	N/A
12/31/2023	N/A	-748	-464	-455	N/A
9/30/2023	N/A	-834	-480	-465	N/A
6/30/2023	N/A	-920	-495	-474	N/A
3/31/2023	N/A	-906	-638	-559	N/A
12/31/2022	N/A	-892	-782	-643	N/A
9/30/2022	13	-810	-846	-640	N/A
6/30/2022	26	-727	-910	-637	N/A
3/31/2022	26	-2,736	-800	-575	N/A
12/31/2021	26	-4,744	-691	-512	N/A
9/30/2021	13	-4,831	-540	-431	N/A
6/30/2021	N/A	-4,917	-390	-350	N/A
3/31/2021	N/A	-2,991	-352	-323	N/A
12/31/2020	N/A	-1,064	-314	-295	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRTH.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRTH.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRTH.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRTH.F's revenue (114.9% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: CRTH.F's revenue (114.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CRTH.F is forecast to be unprofitable in 3 years.

CARsgen Therapeutics Holdings Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies